SANOFI PASTEUR
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Subsidiary
- Established
- 1990-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.sanofipasteur.com
Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children
Completed
- Conditions
- Dengue Hemorrhagic FeverDengueDengue Fever
- First Posted Date
- 2011-11-22
- Last Posted Date
- 2018-01-11
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 667
- Registration Number
- NCT01477671
Sequential Inactivated Poliomyelitis Vaccine Followed by Oral Poliomyelitis Vaccine Versus Oral Poliomyelitis Vaccine
Phase 4
Completed
- Conditions
- PoliomyelitisPolio
- Interventions
- Biological: Injectable inactivated types 1, 2 and 3 poliovirus + Live oral PolioBiological: Live oral poliovirus type 1, 2 and 3
- First Posted Date
- 2011-11-21
- Last Posted Date
- 2015-01-12
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 456
- Registration Number
- NCT01475539
Study of Investigational Pneumococcal Vaccine in Healthy Adults, Toddlers and Infants
Phase 1
Completed
- Conditions
- Pneumococcal InfectionsStreptococcus Pneumoniae InfectionsPneumonia
- Interventions
- Biological: Tris buffered saline (Placebo)Biological: Pneumococcal Vaccine High Dose (Formulation 1)Biological: Pneumococcal Vaccine Middle Dose (Formulation 4)Biological: Pneumococcal Vaccine Low Dose (Formulation 2)Biological: Pneumococcal Vaccine Middle Dose (Formulation 3)
- First Posted Date
- 2011-10-05
- Last Posted Date
- 2018-01-10
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 280
- Registration Number
- NCT01446926
Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants
Phase 3
Completed
- Conditions
- Hepatitis BPoliomyelitisDiphtheriaTetanusWhooping Cough
- Interventions
- Biological: DTaP-IPV-Hep B-PRP~T combined vaccine + Pneumococcal polysaccharideBiological: DTaP-Hep B-IPV // Hib Vaccine + Pneumococcal polysaccharideBiological: DTaP-IPV-Hep B-PRP~T + Pneumococcal polysaccharide vaccine
- First Posted Date
- 2011-10-03
- Last Posted Date
- 2014-07-16
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 1106
- Registration Number
- NCT01444781
Study of an Investigational Pneumococcal Vaccine at Three Dose Levels in Healthy Adults
Phase 1
Completed
- Conditions
- Pneumococcal PneumoniaPneumococcal InfectionsStreptococcus Pneumoniae Infections
- Interventions
- Biological: Pneumococcal vaccine Formulation 1Biological: PlaceboBiological: Pneumococcal vaccine Formulation 2Biological: Pneumococcal vaccine Formulation 3
- First Posted Date
- 2011-09-30
- Last Posted Date
- 2015-03-18
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 100
- Registration Number
- NCT01444352
Study of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra Vaccine
Phase 2
Completed
- Conditions
- Meningococcal InfectionMeningitis
- First Posted Date
- 2011-09-28
- Last Posted Date
- 2014-11-18
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 834
- Registration Number
- NCT01442675
Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose
Phase 4
Completed
- Conditions
- PertussisWhooping CoughTetanusDiphtheria
- Interventions
- Biological: Tetanus Toxoid, Diphtheria Toxoid and Pertussis VaccineBiological: Tetanus and Diphtheria Toxoids Adsorbed For Adult Use
- First Posted Date
- 2011-09-23
- Last Posted Date
- 2022-04-28
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 1330
- Registration Number
- NCT01439165
Regulatory Post-Marketing Surveillance Study for TETRAXIM™
Phase 4
Completed
- Conditions
- PoliomyelitisDiphtheriaTetanusPertussis
- First Posted Date
- 2011-09-20
- Last Posted Date
- 2022-03-28
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 600
- Registration Number
- NCT01437423
Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers
Phase 3
Completed
- Conditions
- Dengue Hemorrhagic FeverDengueYellow Fever
- Interventions
- Biological: Live, attenuated dengue serotype 1, 2, 3, and 4 virusBiological: Yellow Fever VaccineBiological: Measles, mumps, and rubella (MMR) vaccineBiological: Placebo (NaCl)Biological: Pneumococcal Conjugated VaccineBiological: Measles, mumps, and rubella vaccineBiological: Hepatitis A Pediatric VaccineBiological: Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine
- First Posted Date
- 2011-09-19
- Last Posted Date
- 2022-03-25
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 792
- Registration Number
- NCT01436396
Study of Sanofi Pasteur and Lanzhou Institute's Meningococcal (Group A and C) Polysaccharide Vaccine in Children
Phase 4
Completed
- Conditions
- Meningococcal DiseaseMeningitis
- Interventions
- Biological: Meningococcal (Groups A and C) Polysaccharide Vaccine
- First Posted Date
- 2011-09-08
- Last Posted Date
- 2014-05-08
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 666
- Registration Number
- NCT01430611
© Copyright 2025. All Rights Reserved by MedPath